NASDAQ · KPTI
Karyopharm Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for KPTI: Nov 2, 2026
Karyopharm Therapeutics Inc. Common Stock is estimated to report earnings on 11/02/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.15. The reported EPS for the same quarter last year was $-3.82.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.15 | $-1.05 | $-1.26 | 2 |
| Dec 2026 | $-1.08 | $-0.85 | $-1.30 | 2 |
| Mar 2027 | $-1.14 | $-1.14 | $-1.14 | 1 |
| Jun 2027 | $-1.01 | $-1.01 | $-1.01 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · The Motley Fool · Zacks- Fintel · Oct 22, 7:22 PM EDTKaryopharm Therapeutics Inc. Extends Forbearance Period to November 1, 2026Karyopharm Therapeutics Inc. reported that on October 22, 2026, in accordance with Section 19 of the Forbearance Agreement, the applicable parties further extended the date on which the Forbearance Period will end, absent earlier termination, from 11:59 p.m., Eastern time, on Oct
- RTTNews · Aug 31, 9:06 AM EDTKaryopharm Submits SNDA For XPOVIO Plus Ruxolitinib In Myelofibrosis; Stock Up(RTTNews) – Karyopharm Therapeutics Inc. (KPTI) announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking Accelerated Approval for XPOVIO in combination with Ruxolitinib for patients with myelofibrosis.
- RTTNews · Aug 31, 7:52 AM EDTKaryopharm Submits SNDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib(RTTNews) – Karyopharm Therapeutics (KPTI) has submitted a supplemental New Drug Application to the FDA seeking Accelerated Approval for XPOVIO or selinexor in combination with ruxolitinib for patients with myelofibrosis. Karyopharm requested Priority Review, which, if granted, c
- RTTNews · Aug 20, 5:04 PM EDTActive Biotech's Q2 Loss Shrinks As Dosing Begins In Myelofibrosis Trial(RTTNews) – Active Biotech AB (publ) (ACTI.ST), an immunomodulatory treatment company, on Thursday announced interim financial results for the second quarter and registered a marginally lower loss as clinical trials ensued only prior to and after the period.
- The Motley Fool · Aug 20, 9:43 AM EDTKaryopharm (KPTI) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 14, 1:24 AM EDTKaryopharm Q2 Net Loss Expands; Reaffirms 2026 Revenue Guidance; Plans SNDA For Selinexor In August(RTTNews) – Karyopharm Therapeutics Inc. (KPTI), a commercial-stage pharmaceutical company, reported financial results for the second quarter of 2026, reflecting a wider net loss and provided an update on the company's myelofibrosis program. In addition, the company reaffirmed th
- Zacks · Aug 13, 8:50 AM EDTKaryopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue EstimatesKaryopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -51.63% and +5.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 11, 5:25 PM EDTAquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue EstimatesAquestive Therapeutics (AQST) delivered earnings and revenue surprises of -80.00% and +12.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Aug 7, 11:45 AM EDTWeekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data(RTTNews) – This week's biotech roundup captured a mix of regulatory wins, restructuring action, and deal momentum driving sector sentiment. FDA and EU approvals spanned oncology, vaccines and rare disease, while layoffs and cost-saving measures underscored operational tightening
- Zacks · Aug 6, 7:10 PM EDTRelay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue EstimatesRelay Therapeutics (RLAY) delivered earnings and revenue surprises of 0.00% and -86.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 31, 10:39 AM EDTKaryopharm's Phase 3 Endometrial Cancer Trial Misses Endpoint; Stock Slides(RTTNews) – Karyopharm Therapeutics Inc. (KPTI), announced yesterday topline results from its Phase 3 XPORT-EC-042 trial evaluating Selinexor as a maintenance-only therapy in patients with TP53 wild-type advanced or recurrent endometrial cancer.
- Zacks · Jul 30, 8:35 AM EDTMadrigal (MDGL) Reports Q2 Loss, Beats Revenue EstimatesMadrigal (MDGL) delivered earnings and revenue surprises of +21.96% and +4.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Karyopharm Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.